| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.9 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |